UroGen Pharma Ltd (NASDAQ:URGN) has a beta value of 0.35 and has seen 2.09 million shares traded in the last trading session. The company, currently valued at $659.33M, closed the last trade at $14.3 per share which meant it lost -$0.35 on the day or -2.39%% during that session. The URGN stock price is -26.92% off its 52-week high price of $18.15 and 76.08% above the 52-week low of $3.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.37 million shares traded. The 3-month trading volume is 2.69 million shares.
The consensus among analysts is that UroGen Pharma Ltd (URGN) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 7 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Sporting -2.39%% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the URGN stock price touched $14.3 or saw a rise of 8.39%. Year-to-date, UroGen Pharma Ltd shares have moved -15.23%, while the 5-day performance has seen it change 18.87%. Over the past 30 days, the shares of UroGen Pharma Ltd (NASDAQ:URGN) have changed 242.93%. Short interest in the company has seen 3.92 million shares shorted with days to cover at 1.72.
Wall Street analysts have a consensus price target for the stock at $23.5, which means that the shares’ value could jump 39.15% from current levels. The projected low price target is $16.0 while the price target rests at a high of $31.0. In that case, then, we find that the current price level is -116.78% off the targeted high while a plunge would see the stock gain -11.89% from current levels.
UroGen Pharma Ltd (URGN) estimates and forecasts
The company’s shares have gained 26.21% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.39% over the past 5 years.
URGN Dividends
UroGen Pharma Ltd is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
Insiders own 6.87% of the company shares, while shares held by institutions stand at 105.33% with a share float percentage of 113.10%. Investors are also buoyed by the number of investors in a company, with UroGen Pharma Ltd having a total of 192.0 institutions that hold shares in the company. The top two institutional holders are RTW INVESTMENTS, LP with over 3.56 million shares worth more than $59.69 million. As of 2024-06-30, RTW INVESTMENTS, LP held 9.661% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 3.3 million shares as of 2024-06-30. The firm’s total holdings are worth over $55.37 million and represent 8.9621% of shares outstanding.
